Veracyte | VCYT - Operating Profit


Veracyte reported $24.63M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agenus USD 14.4M 19.26M Dec/2025
Agilent USD 353M 90M Dec/2025
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Bruker USD 76.3M 7.6M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Illumina USD 256M 6M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Laboratory Of America USD 382M 15.3M Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Myriad Genetics USD -3M 20.3M Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Siemens EUR 2.57B 3M Dec/2025
Sonic Healthcare AUD 435.76M 193.66M Dec/2024
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025
Waters USD 270.52M 78.4M Dec/2025